6 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Recruiting 6, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 4 | Recruiting 3, Not yet recruiting 1 |
Follow Tegavivint: new trials by email Literature Review of Tegavivint trials Research Report on Tegavivint
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma Zanzalintinib, Tegavivint - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 36 | 2026-12-01 | 2026-10-16 |
| Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma Tegavivint - Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | HonorHealth Research Institute | 126 | 2026-02-17 | 2026-03-11 |
| Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma Tegavivint, Gemcitabine - Osteosarcoma Recurrent, Osteosarcoma in Children | Phase 1 | Recruiting | Emory University | 24 | 2026-01-22 | 2026-10-19 |
| A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma Tegavivint, Lenvatinib, Cabozantinib - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | Iterion Therapeutics | 178 | 2023-09-13 | 2025-07-04 |
| Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Recruiting | Lapo Alinari | 18 | 2023-03-06 | 2026-02-27 |
| Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer Osimertinib, Tegavivint, Echocardiography Test - Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 25 | 2022-01-18 | 2026-09-15 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Tegavivint for the Treatment of Relapsed or Refractory Leukemia Decitabine, Tegavivint - Recurrent Leukemia, Refractory Leukemia | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 9 | 2021-09-27 | 2026-08-25 |
| Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 Tegavivint - Desmoid Tumor | Phase 1 | Completed | Iterion Therapeutics | 24 | 2018-07-15 | 2023-03-01 |
Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Desmoid Tumors (2) · Osteosarcoma (2) · Adenomatous Polyposis Coli (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Hepatoblastoma (1) · Leukemia (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Neuroblastoma (1) · Ovarian Neoplasms (1) · Sarcoma, Ewing (1)
Iterion Therapeutics (2) · Children's Oncology Group (1) · Emory University (1) · HonorHealth Research Institute (1) · Lapo Alinari (1) · M.D. Anderson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · University of Texas Southwestern Medical Center (1)
United States (9) · Canada (2)
David Hsieh, MD (1) · Lapo Alinari, MD, PhD (1) · Regan M Memmott, M.D., Ph.D (1) · Sarah B Whittle (1) · Tapan M Kadia (1) · Thomas Cash, MD, MSc (1)
UM1CA228823 (1)